Program
visugromab
Also written as “Visugromab (CTL-002)”, “Visugromab RDE (recommended dose for expansion)” and “Visugromab 6mg/kg”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Cachexia · Urinary Bladder Neoplasms, led by CatalYm.
Furthest: phase 3, since Jul 31, 20256 company-led studies, 5 open or runningNext primary completion: Apr 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CatalYm | 65 open or running | phase 3since Jul 31, 2025 | Jan 14, 2021 | Apr 30, 2028phase 2 · NCT04725474 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 14, 2021First study: phase 2 study in Solid Tumor, AdultFirst studyNCT04725474 · 199 enrolled · Germany, Spain, Switzerland
- Aug 23, 2023Phase 2 study in Urinary Bladder NeoplasmsNCT06059547 · 31 enrolled · Italy
- Jul 10, 2025Phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07098988 · 107 planned · United States, Germany, Italy and more
- Jul 31, 2025Phase 3 study in CachexiaNCT07112196 · 518 planned · United States, Bulgaria, Czechia and more
- Oct 20, 2025Phase 2 study in Carcinoma, HepatocellularNCT07219459 · 104 planned · United States, France, Germany and more
- Nov 19, 2025Phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07246863 · 131 planned · United States, Germany, Italy and more
Ahead
- Apr 30, 2028Primary completion: phase 2 study in Solid Tumor, AdultNCT04725474
- Mar 31, 2029Primary completion: phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07098988
- Sep 2029Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07219459
- Oct 1, 2029Primary completion: phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07246863
TargetBeta
“A humanized, hinge-stabilized immunoglobulin G4 (IgG4) monoclonal antibody directed against growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-deri”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rilogrotugrule | LG Chem | phase 3 | 3 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer · United States, Germany, Italy and more | 2 | Recruiting | Oct 1, 2029 | 131 |
| NCT07219459Carcinoma, Hepatocellular · United States, France, Germany and more | 2 | Recruiting | Sep 2029 | 104 |
| NCT07112196Cachexia · United States, Bulgaria, Czechia and more | 3 | Recruiting | Dec 2029 | 518 |
| NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer · United States, Germany, Italy and more | 2 | Recruiting | Mar 31, 2029 | 107 |
| NCT06059547Urinary Bladder Neoplasms · Italy | 2 | Completed | Oct 16, 2025 | 31 |
| NCT04725474Solid Tumor, Adult · Germany, Spain, Switzerland | 2 | Active, not recruiting | Apr 30, 2028 | 199 |
How it is read
Names in the registry
- “Visugromab (CTL-002)”, 4 entries
- “Visugromab RDE (recommended dose for expansion)”, 1 entry
- “Visugromab 6mg/kg”, 1 entry
- “Visugromab”, 1 entry
- “visugromab (CTL-002)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Carcinoma, Hepatocellular, 1 study
- Cachexia, 1 study
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.